Loading provider…
Loading provider…
Hematology & Oncology Physician in La Jolla, CA
NPI: 1417120080Primary Practice Location
SCRIPPS GREEN HOSPITAL
10666 N Torrey Pines Rd, La Jolla, CA
Primary Employer
Scripps Clinic
scripps.org
HQ Phone
Get MD Darren's Phone NumberMobile
Get MD Darren's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
IL State Medical License
2024 - 2026
CA State Medical License
2003 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 2002
Scripps Clinic/Scripps Green Hospital
Fellowship • Hematology and Medical Oncology
2005 - 2008
University of California Davis Health
Residency • Internal Medicine
2002 - 2005
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 290 | 883 |
| 2 | 96413Infusion of chemotherapy into a vein up to 1 hour | 148 | 735 |
| 3 | 96375Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 127 | 1,460 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 119 | 332 |
| 5 | J1626Injection, granisetron hydrochloride, 100 mcg | 110 | 5,740 |
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.
Authors: Vincent Miller, Munveer Bhangoo, Jonathan Hermel
Journal: Oncotarget
Publication Date: 2018-11-09
Hairy cell leukemia: current therapies and future directions
Authors: Alan Saven, Gregory Vosganian
Publication Date: 2010-12
Authors: Apostolia Tsimberidou, Heinz-Josef Lenz, Michael Saville
Journal: Cancer Chemother Pharmacol
Publication Date: 2024-09-23
Lead Sponsor: Celularity Incorporated
Intervention / Treatment: DRUG: Trastuzumab, DRUG: Pembrolizumab, DRUG: Cyclophosphamide, DRUG: Mesna, DRUG: Fludarabine, BIOLOGICAL: CYNK-101, DRUG: Recombinant Human Interleukin-2
Lead Sponsor: Aravive, Inc.
Intervention / Treatment: DRUG: Gemcitabine, DRUG: Nab paclitaxel, DRUG: batiraxcept
Lead Sponsor: Halozyme Therapeutics
Intervention / Treatment: DRUG: Atezolizumab, DRUG: PEGPH20, DRUG: CIS, DRUG: GEM